Expert Ratings for Quest Diagnostics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 Wall Street analysts have provided ratings for Quest Diagnostics (NYSE:DGX) with all 5 being indifferent. The average 12-month price target for DGX is $137.2, with a high of $149.00 and a low of $130.00. This target has decreased by 2.0% from the previous target of $140.00. Analysts provide these ratings based on research, financial statements, and insider information, although it is important to remember that their predictions are not infallible.

December 07, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Quest Diagnostics (DGX) has received a neutral consensus rating from analysts, with an average price target of $137.2, which is a 2.0% decrease from the previous target of $140.00.
The unanimous indifferent rating from analysts suggests that there is no strong sentiment driving the stock price in either direction. The slight decrease in the average price target may indicate a modest adjustment in expectations, but not significant enough to warrant a strong short-term price movement. The importance is rated at 75 due to the relevance of analyst ratings to investors, but not at the highest level as these are not drastic changes. The confidence level is at 80, acknowledging that while analyst ratings are influential, they are not the sole factor affecting stock prices.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100